hsa-mir-374: Hsa-mir-374 is a microRNA that has been detected in plasma and has been linked to various neurodegenerative disorders, including Amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease, as well as immune-related diseases such as T‐cell acute lymphoid leukemia and inflammatory processes in diabetes [Gimenes-Teixeira et al., 2013; Qian et al., 2015; PMC9713411]. It has been used as a reference for miRNA expression normalization in different tissues and samples, such as solid tissues [PMC4919505], cultured cells [PMC4919505], and serum samples [PMC4919505]. Hsa-mir-374 expression has been found to co-occur with hsa-miR-218 in various independent experiments [PMC3479204]. It has also been used as a housekeeping control in different studies involving miRNA expression analysis [PMC10126132; PMC3195087]. Hsa-mir-374 has been identified as one of the potential biomarkers for distinguishing between benign and malignant parotid neoplasms based on its differential expression in whole saliva samples [PMC4636154]. Furthermore, hsa-mir-374 is involved in the regulation of MECP2 expression and activity, interferon alpha/beta signaling (hsa-miR-1227), oncogene-induced senescence, glycosaminoglycan metabolism (hsa-miR-148a), and transcriptional regulation of granulopoiesis [PMC7582243]. It is also implicated in the activation of Wnt/b-catenin signaling pathway during the implantation process [PMC5339930].

hsa-mir-374a: Hsa-mir-374a is a miRNA-like sequence identified within the env and the gag-pol encoding regions of several HIV-1 strains [PMC7041288]. Previous studies have shown that hsa-mir-374a can reduce the risk of colorectal cancer [PMC6221654]. In a study, the top three lncRNAs were AC133528, AC109927, and AL021707; the top three mRNAs were TMEM88B, GHRHR, and ZC3HAV1L; the top three miRNAs were hsa-mir-545, has-mir-548k, and hsa-mir-374a; and the top three DNA methylation sites were cg17863551, cg08491964, and cg04067612 [PMC8176021].